Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
132M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
17.7M
-
Shares change
-
-6.59M
-
Total reported value, excl. options
-
$159M
-
Value change
-
-$170M
-
Put/Call ratio
-
1.61
-
Number of buys
-
34
-
Number of sells
-
-42
-
Price
-
$8.98
Significant Holders of RAPT Therapeutics, Inc. - Common Stock (RAPT) as of Q1 2024
104 filings reported holding RAPT - RAPT Therapeutics, Inc. - Common Stock as of Q1 2024.
RAPT Therapeutics, Inc. - Common Stock (RAPT) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.7M shares
of 132M outstanding shares and own 13.4% of the company stock.
Largest 10 shareholders include Column Group LLC (2.68M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.03M shares), MORGAN STANLEY (1.91M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.5M shares), PERCEPTIVE ADVISORS LLC (1.22M shares), Redmile Group, LLC (662K shares), STATE STREET CORP (659K shares), Euclidean Capital LLC (658K shares), Cormorant Asset Management, LP (497K shares), and TWO SIGMA INVESTMENTS, LP (426K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.